Atlas Logo
Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably - Two (BioFINDER Two)
Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably - Two logo
BACK
Sample details

As an extension of BioFINDER One, BioFINDER Two follows a new cohort of individuals with and without cognitive decline, impairment or dementias. BioFINDER Two follows both middle-aged participants and elderly participants. The cohort includes five sub-cohorts. Cohort A: 300 cognitively healthy middle-aged participants (40-65 years) as well as 40 participants aged 20-40 years; Cohort B: 300 cognitively healthy elderly participants (65-100 years); Cohort C: 800 participants with either subjective cognitive decline or mild cognitive impairment (40-100 years); Cohort D: 400 participants with mild to moderate dementia due to Alzheimer’s disease (40-100 years); and Cohort E: over 500 participants with primary neurodegenerative disorders other than Alzheimer’s disease (40-100 years). All participants are fluent in Swedish, some Cohort A and B participants are also in the Malmö Offspring study and Cohort C, D and E participants were recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. This has resulted in 2,550 participants and each group is followed up every 1-2 years, for 2, 6 or 8 years.

Study design
Cohort

Number of participants at first data collection

340 (Cohort A participants)

300 (Cohort B participants)

1,000 (Cohort C participants)

400 (Cohort D participants)

510 (Cohort E participants)

Recruitment is ongoing

Age at first data collection

20 - 65 years (Cohort A participants)

40 - 100 years (Cohort C participants)

40 - 100 years (Cohort D participants)

40 - 100 yeats (Cohort E participants)

65 - 100 years (Cohort B participants)

Participant year of birth

Varied (participants)

Participant sex
All

Representative sample at baseline?
No

Sample features

Adults
Middle-aged people
Older and elderly people
Patients and clinical populations
Dataset details

Country

Sweden

Year of first data collection

2017

Primary Institutions

Lund University (Lunds Universitet)

Skåne University Hospital (Skånes universitetssjukhus, SUS)

Links

biofinder.se/two/

clinicaltrials.gov/study/NCT03174938

doi.org/10.1101%2F2023.07.14.23292650

Profile paper DOI
Not available

Funders

Knut and Alice Wallenberg Foundation

Lund University (Lunds Universitet)

Marianne and Marcus Wallenberg Foundation (Marianne och Marcus Wallenberg Stiftelse)

National Institutes of Health (NIH)

Parkinson Research Foundation

Ongoing?
Yes

Data types collected

neuroImagingData
mentalHealthData
Quantitative data collection
  • Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
Qualitative data collection
  • None
Neuroimaging data collection
  • Arterial Spin Labelling (ASL)
  • Diffusion Tensor Imaging (DTI)
  • Functional magnetic resonance imaging (fMRI)
  • Magnetic Resonance Imaging (MRI)
  • Magnetic Resonance Spectroscopy (MRS)
  • Positron Emission Tomography (PET)
Linked or secondary data
  • None
Features

Engagement

  • None
  • Keywords

    Alzheimer's disease (AD)
    Biological samples/biospecimens
    Biomarkers
    Cognitive ageing and decline
    Dementia
    Diagnostic markers
    Disease prevention
    Neuroimaging
    Parkinson's disease (PD)

    Consortia and dataset groups

    BioFINDER
    Contact us

    |

    FAQS

    |

    Privacy

    |

    © 2024 Louise Arseneault

    Platform by Delosis